Leerink Partners Maintains Outperform Rating on United Therapeutics
Leerink Partners maintained its Outperform rating and $725 price target for United Therapeutics. The target implies 36.0% upside from the Oct. 16 close of $533.12.
Leerink Partners maintained its Outperform rating and $725 price target for United Therapeutics. The target implies 36.0% upside from the Oct. 16 close of $533.12.